Josh Jennings, Cowen & Co. (5/11/18) "VIVE improved traction with its hybrid direct distributor sales model in select countries in Europe and gained new regulatory approvals in three Latin American countries."
BioTuesdays (2/20/18) "DXD remains on track to complete all phases of the test development and analytical validation by April 2018."
Chris Parry, Equity Guru (10/5/17) "RHT now has 1000 patients into their system from two customers, and expect somewhere between 2000 and 2500 to be added next month."
Brian Marckx, Zacks Equity Research (8/21/17) "One of the major operational items of interest since VIVE's Q1 update is an agreement with InControl Medical LLC."
BioTuesdays Publishing Co. (4/4/17) "DXD successfully completing internal analytical assay validation for its Hodgkin's Lymphoma test."
Magdalena Kegel, Alzheimer's News Today (3/22/17) "DXD has developed a simple cheek swab to identify patients with Alzheimer's disease."
Etienne Moshevich, Alphastox.com (3/2/17) "I wanted to send out a quick update on DXD after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity."
Shane Matte, BioTuesdays (2/23/17) "The validation program for DXD's Hodgkin's lymphoma test (Telo-HL) is under way."
Jennifer Poland, BioTuesdays (12/7/16) "Preliminary results suggest DXD has a promising molecular imaging technology with potential to improve the management of AC patients who present with multiple lung lesions."
Alphastox.com (11/15/16) "DXD is one of my top picks for the year and through 2017."
Brian Marckx, Zacks Equity Research (10/13/16) "VIVE continues to make substantive progress towards their quest to commercialize the Viveve System in the U.S."
James West, Midas Letter (9/7/16) "DXD is a diagnostic technology platform that analyzes changes in telomere structures within DNA to determine aspects and characteristics of deadly diseases like cancer and Alzheimer's Disease."
Anthony Vendetti, Maxim Group (6/21/16) "VIVE is well-positioned to gain regulatory clearances in additional countries, which should lead to the Viveve System gaining further traction."
Brian Marckx, Zacks Equity Research (6/15/16)
Anthony Vendetti, Maxim Group (4/27/16) "The positive results of VIVE's VIVEVE I clinical trial builds upon the two previous clinical studies conducted in the U.S. and Japan."
Gregory Chodaczek, Sterne Agee (4/22/16)
Kayt Sukel, Fortune (9/10/15) "TIME Magazine named AEMD's Hemopurifier one of the best inventions of 2014."
Canacccord Genuity's Morning Coffee (6/9/15) "HLTH has added its its second ancillary services resume stream of the quarter."
Henry McCusker, RegMed Investors (4/16/15) "STEM expects to release six-month interim Phase 2 data later this year."
RedChip Companies Inc. (12/16/14) "Pappajohn's show of faith in CGIX speaks volumes about its potential."
Dr. Yi Chen, Aegis Capital (12/5/14) "We believe CGIX's revenues will continue to grow in coming quarters."
Thomas Pfister, RedChip Companies Inc. (11/10/14) "CGIX's Q3/14 revenue grew to $3.22M, representing 90% YOY growth."
Debjit Chattopadhyay, ROTH Capital Partners (9/30/14) "The new COO's expertise could be a key asset in NEO's product launch."
Scott Power, Morgans (9/5/14) "IPD has had a transformational event; we increase our price target for the company."
Matthijs Smith, Canaccord Genuity (9/3/14) "IPD's major milestone has secured the expanded market; we are increasing our target price."
Dr. Ram Selvaraju, Aegis Capital (9/3/14) "CE marking allows CGIX's FHACT to be sold freely within the European Economic Area."
Debjit Chattopadhyay, ROTH Capital Partners (8/21/14) "For NEO, we expect test volume growth of ~25% in 2014, ~18% in 2015."
Debjit Chattopadhyay, ROTH Capital Partners (8/15/14) "NEO bolstered its balance sheet with ~$30M via a secondary offering."
Dr. Ram Selvaraju, Aegis Capital (8/14/14) "CGIX has sufficient capital to fund operations to break even status."
Sung Ji Nam, Cantor Fitzgerald (8/14/14) "We continue to remain optimist on CGIX in the near to medium term."
Jason Napodano, Seeking Alpha (8/6/14) "A rapid and economical test like AMBS' LymPro could be used to improve Alzheimer's patient enrollment for future clinical trials."
Debjit Chattopadhyay, ROTH Capital Partners (8/4/14) "NEO has an extensive track record of growing test volume and high client-retention rates."
The Life Sciences Report interview with Debjit Chattopadhyay (7/24/14) "Watch out for NEO; it is significantly undervalued given the opportunities that lie ahead."
Tony Schwartz, Seeking Alpha (7/23/14) "In Q2/14, NEO posted record revenue of $20.7M, up 32% from Q2/13."
Grant Zeng, Zacks Small-Cap Research (7/21/14) "NEO is becoming America's premier cancer testing laboratory."
Amanda Murphy, William Blair (7/18/14) "We are encouraged by NEO's volume growth of 40% in Q2/14."
Robert Wasserman, Dawson James Securities (7/18/14) "Investors in NEO have a lot to look forward to in the future."
Amanda Murphy, William Blair (7/11/14) "NEO's newly expanded NGS menu solidifies the company's market position."
Jerry Isaacson, LifeSci Advisors (7/1/14) "CGIX's two acquisitions should lead to stable revenue growth."
Christian Glennie, Edison Investment Research (6/30/14) "Potential FDA clearance for VRS' Aura is a key near-term catalyst."
Sung Ji Nam, Cantor Fitzgerald (6/26/14) "CGIX progresses still with new commercial and clinical collaborations."
Amanda Murphy, William Blair (6/23/14) "NEO's Q2/14 revenue is expected to be $20–$20.5M (about 30% growth)."
Dr. Ram Selvaraju, Aegis Capital (6/9/14) "CGIX entered into a partnership with AstraZeneca CAMCAR."
Debjit Chattopadhyay, ROTH Capital Partners (6/9/14) "Our 2015 above-consensus NEO estimates could become the consensus."
Brian Marckx, Zacks Small-Cap Research (6/5/14) "Cancer Research accepted VRS' Aura study analysis for publication."
The Life Sciences Report Interview with Jason Kolbert (6/4/14) "I think that 2015 will be transformational, as KOOL gets ready to show us top-line data."
Thomas Pfister, RedChip Companies Inc. (6/4/14) "Meaningful revenues from CGIX's FHACT could be seen in Q3/14."
Christian Glennie, Edison Investment Research (6/2/14) "A key, near-term catalyst for VRS is 501(k) FDA clearance for Aura."
Jerry Isaacson, LifeSci Advisors (5/16/14) "CGIX's revenue increased by 17% and test volume by 45% compared to the same period in 2013."
Rohit Vanjani, Oppenheimer & Co. (5/16/14) "We believe OPK's 4Kscore will serve as a better guide for physicians in assessing high-grade prostate cancer."
Dr. Ram Selvaraju, Aegis Capital (5/15/14) "CGIX's announced acquisition could lead to future growth."
Debjit Chattopadhyay, ROTH Capital Partners (5/12/14) "We initiate coverage on NEO with a Buy rating."
Brian Marckx, Zacks Small-Cap Research (5/6/14) "VRS' Aura continues to be recognized as one of the leading novel medical technologies throughout the world."
Zarak Khurshid, Wedbush (5/5/14) "We are reaffirming our Outperform rating on FMI."
Grant Zeng, Zacks Small-Cap Research (4/24/14) "We continue to rate NEO's shares Outperform."
Amanda Murphy, William Blair (4/23/14) "NEO's ability to expand its gross margin, win new accounts and beat projections is encouraging."
The Life Sciences Report Interview with Grant Zeng (4/17/14) "There is great potential for NEO to grow in the future."
Henry McCusker, Scimitar Equity (4/16/14) "BLFS achieved significant growth in sales of its proprietary HypoThermosol and CryoStor biopreservation media products."
Jerry Isaacson, LifeSci Advisors (4/14/14) "CGIX launched a new test to detect mutations in the CALR gene."
Brian Marckx, Zacks Small-Cap Research (4/10/14) "VRS closed a private placement for gross proceeds of $481K."
Jerry Isaacson, LifeSci Advisors (4/1/14) "CGIX has several ways to tap an estimated $6B lab testing market."
Sung Ji Nam, Cantor Fitzgerald (4/1/14) "We are initiating coverage on CGIX with a Buy rating."
Dr. Ram Selvaraju, Aegis Capital (3/27/14) "Gross margins for CGIX's base business could double in 18–24 months."
Rohit Vanjani, Oppenheimer & Co. (3/13/14) "We are initiating coverage of OPK with an Outperform rating; the diagnostic products represent the nearest-term opportunity."
Tech Guru, Seeking Alpha (3/10/14) "After VNRX closed its capital placement raising $3M, the company has ample cash."
The Life Sciences Report Interview with Ben Haynor (3/5/14) "The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal."
Debjit Chattopadhyay, Emerging Growth Stocks (3/4/14) "NEO could generate $5.5–12M for FY/15 and FY/16 from its Covance deal."
Eun Yang, Jefferies & Co. (2/28/14) "Preclinical pharmacokinetic data for OPK's FVIIa-CTP are encouraging."
The Life Sciences Report Interview with Debjit Chattopadhyay (2/27/14) "NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level."
Grant Zeng, Zacks Small-Cap Research (2/20/14) "NEO reported record revenue for Q4/13, the highest in its history."
Drew Jones, Stephens Inc. (2/14/14) "NEO is a very attractive investment; we are initiating coverage."
Chris Bunge, Seeking Alpha (2/11/14) "CGIX has positioned itself to benefit from the transition of traditional diagnostics to genomic-based testing."
Dr. Ram Selvaraju, Aegis Capital (2/10/14) "CGXI is a leader in the molecular diagnostics field with the ability to generate high-margin revenue."
Jason Napodano, Zacks Small-Cap Research (1/22/14) "We are hoping for U.S. full device clearance for DRIO's Dario by the end of 2014."
PropThink, Seeking Alpha (1/21/14) "2014 will be a key year for BLFS as it moves closer to operating profitability."
Amanda Murphy, William Blair (1/8/14) "We are initiating coverage on NEO with an Outperform rating."
The Life Sciences Report Interview with Brian Marckx (12/19/13) "VRS's Aura device for noninvasive skin cancer detection is superior in accuracy and much faster."
Thomas Pfister, RedChip Companies Inc. (12/17/13) "CGIX is accelerating its sales and marketing strategy."
The Life Sciences Report Interview with Ram Selvaraju (12/5/13) "DRIO is developing a very interesting approach to diagnostics at the level of data capture."